STOCK TITAN

Ra Medical Systems Announces Granting of New US Patent

Rhea-AI Impact
(Moderate)
Rhea-AI Sentiment
(Neutral)
Tags

FORT MILL, SC / ACCESSWIRE / March 9, 2022 / Ra Medical Systems, Inc. (NYSE American:RMED) today announced that it has been notified of a new patent granted by the USPTO covering technology utilized in its VIVO product. The patent, number D980,420 S, entitled "Kit of Positioning Patches", was issued on March 7, 2023. The patent covers technology used in the disposable components of the VIVO product.

Ra Medical Systems, Inc., Thursday, March 9, 2023, Press release picture

Ra Medical Systems, Inc., Thursday, March 9, 2023, Press release picture

David Jenkins, Executive Chairman of RMED, commented, "This newly issued patent joins a robust estate of intellectual property accumulated by our company. For the electrophysiology products, we have now have 36 issued patents and 15 application in process. Additionally, we have 15 patents and patent applications licensed into the company covering the VIVO technology. As a small medical device technology company, we believe the obtaining of IP is critical to our future and to the value of our company. We are quite pleased that another US patent has been granted to us."

About VIVO

Catheter Precision's VIVO™ (View Into Ventricular Onset), is a non-invasive 3D imaging system that enables physicians to identify the origin of ventricular arrhythmias pre-procedure, thereby streamlining workflow and reducing procedure time. VIVO has received marketing clearance from the U.S. FDA and has the CE mark.

About Ra Medical Systems

Ra Medical, and its wholly owned subsidiary Catheter Precision, is an innovative U.S.-based medical device company bringing new solutions to market to improve the treatment of cardiac arrhythmias. It is focused on developing groundbreaking technology for electrophysiology procedures by collaborating with physicians and continuously advancing its products.

CONTACTS:

At the Company

David Jenkins
973-691-2000
mhuck@catheterprecision.com

SOURCE: Ra Medical



View source version on accesswire.com:
https://www.accesswire.com/742976/Ra-Medical-Systems-Announces-Granting-of-New-US-Patent

Ra Medical Systems, Inc.

NYSE:RMED

RMED Rankings

RMED Latest News

RMED Stock Data

3.84M
4.60M
36.85%
11%
1.26%
Surgical and Medical Instrument Manufacturing
Manufacturing
Link
US
Carlsbad

About RMED

advanced excimer laser-based vascular and dermatological therapies we are a commercial-stage medical device company leveraging our advanced excimer laser-based platform for use in the treatment of vascular and dermatological diseases. we believe our products enhance patients’ quality of life by restoring blood-flow in arteries and clearing chronic skin conditions. we currently manufacture and market two lines of products: dabra catheter and laser is cleared by the u.s. fda as a tool for the minimally invasive endovascular treatment of vascular blockages resulting from lower extremity vascular disease, which includes peripheral artery disease (pad), which commonly occurs in the legs. pharos excimer laser pharos is designed for use in the treatment of inflammatory skin conditions and is fda cleared as a tool used in the treatment of psoriasis, atopic dermatitis, and leukoderma. our goal is to become the leading medical device company marketing excimer lasers as tools for the treatment of